Corneal Perforation Associated With Tralokinumab
This case represents the first reported instance of corneal perforation potentially related to tralokinumab. Although ocular side effects of IL-13-targeted therapies are typically mild, this report highlights the possibility of severe complications. Given the increasing use of biologic agents in dermatology, awareness of rare but potentially vision-threatening adverse effects is essential. In suspected cases, early ophthalmologic evaluation and multidisciplinary management are crucial for preventing poor outcomes in patients receiving tralokinumab.
Authors
- Rosalía Méndez-Fernández (ORCID: https://orcid.org/0000-0001-8004-967X)
- Álvaro Iglesias‐Puzas (ORCID: https://orcid.org/0000-0001-5849-4021)
- Ricardo Cuiña‐Sardiña (ORCID: https://orcid.org/0000-0003-3880-4621)
- David Díaz‐Valle (ORCID: https://orcid.org/0000-0003-4450-7471)
- Javier García-Bardera (ORCID: https://orcid.org/0000-0001-8622-8695)
- Mireia García-Bermúdez
- Sergio Pernas-Martin
Institutions
- Hospital Clínico San Carlos (ES)
- Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (ES)
- Hospital Universitario Infanta Sofía (ES)
Publication Details
- Journal
- Cornea
- Published
- 2025-06-17
- DOI
- https://doi.org/10.1097/ico.0000000000003922
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00